<?xml version='1.0' encoding='utf-8'?>
<document id="30630341"><sentence text="Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention." /><sentence text="The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (P-PCI)" /><sentence text=" In turn, this leads to a gap in platelet inhibition, exposing patients to an increased risk of early thrombotic complications and underscoring the need to define strategies associated with more effective platelet inhibition in the peri-primary percutaneous coronary intervention period" /><sentence text=" Cangrelor is an intravenous P2Y12 inhibitor with prompt and potent antiplatelet effects" /><sentence text=" However, to date, there are limited data on the effects of cangrelor used in combination with ticagrelor in patients undergoing primary percutaneous coronary intervention"><entity charOffset="95-105" id="DDI-PubMed.30630341.s5.e0" text="ticagrelor" /></sentence><sentence text=" Moreover, questions have emerged on the potential for drug-drug interactions during the transition from cangrelor to oral P2Y12 inhibitors" /><sentence text="" /><sentence text="This was a prospective, randomized, double-blind, placebo-controlled pharmacodynamic study conducted in patients undergoing primary percutaneous coronary intervention (n=50) who were randomized to treatment with either cangrelor or matching placebo (bolus followed by 2-hour infusion)" /><sentence text=" All patients received ticagrelor 180-mg loading dose administered as crushed tablets at the time of cangrelor/placebo bolus administration"><entity charOffset="23-33" id="DDI-PubMed.30630341.s9.e0" text="ticagrelor" /></sentence><sentence text=" Pharmacodynamic analyses were performed at 8 time points" /><sentence text=" Pharmacodynamic effects were measured as P2Y12 reaction units by VerifyNow and platelet reactivity index by vasodilator-stimulated phosphoprotein" /><sentence text="" /><sentence text="Compared with placebo, cangrelor was associated with reduced P2Y12 reaction units as early as 5 minutes after bolus, which persisted during the entire duration of drug infusion, including at 30 minutes (63 [32-93] versus 214 [183-245]; mean difference, 152 [95% CI, 108-195]; P&lt;0Â·001; primary end point)" /><sentence text=" Parallel findings were shown with platelet reactivity index" /><sentence text=" Accordingly, high on-treatment platelet reactivity rates were reduced with cangrelor" /><sentence text=" After discontinuation of cangrelor/placebo infusion, there were no differences in levels of platelet reactivity between groups, ruling out a drug-drug interaction when cangrelor and ticagrelor are concomitantly administered" /><sentence text="" /><sentence text="In patients undergoing primary percutaneous coronary intervention, cangrelor is an effective strategy to bridge the gap in platelet inhibition associated with the use of oral P2Y12 inhibition induced by ticagrelor" /><sentence text=" Ticagrelor can be administered as a crushed formulation concomitantly with cangrelor without any apparent drug-drug interaction"><entity charOffset="1-11" id="DDI-PubMed.30630341.s19.e0" text="Ticagrelor" /></sentence><sentence text=" The clinical implications of these pharmacodynamic findings warrant investigation in an adequately powered clinical trial" /><sentence text="" /><sentence text="URL: https://www" /><sentence text="clinicaltrials" /><sentence text="gov " /><sentence text=" Unique identifier: NCT03247738" /><sentence text="" /></document>